Climb Bio

#ICYMI At Climb Bio, we're dedicated to improving the lives of the approximately 50 million Americans—and countless others worldwide—living with immune-mediated diseases. ? Our new name, Climb Bio, reflects the journey each patient faces and our commitment to advancing transformative treatments. By harnessing new discoveries in molecular immunology and antibody engineering, and listening to the voices of scientists, physicians, and patients, we’re determined to make a real difference. ? Together, we’re climbing toward a future with better treatments and brighter outcomes. ? Watch the full replay of our Investor Day: https://lnkd.in/g4nVmyg5.

#ICYMI For those living with rare and orphan diseases like chronic ITP, budoprutug aims to offer a personalized, treat-to-target approach. Nishi Rampal, MD, Head of Clinical Development at Climb Bio, shares our vision for meeting the unique needs of each patient. Catch the webcast replay at 1:05:17 for more insights: https://lnkd.in/g4nVmyg5. hashtag #ClimbBio hashtag #ClimbTogether

#ICYMI: Dr. Frank Cortazar, Director at the New York Nephrology Vasculitis and Glomerular Center and principal investigator for the Phase 1b primary membranous nephropathy (pMN) study, shared insights into Climb Bio’s lead asset, budoprutug and its potential to treat this condition. The effect of budoprutug on proteinuria in pMN patients observed in a Phase 1b clinical trial was promising, offering a potential pathway for true immune reset and even a cure in some cases. There is a high unmet need in pMN, and this development could alter the treatment landscape. Watch the webcast replay at 27:36 to learn more: https://lnkd.in/g4nVmyg5. hashtag #ClimbBio hashtag #ClimbTogether

Thrilled to share that Climb Bio will be at the Stifel 2024 Healthcare Conference in NYC on November 18-19! Don’t miss the fireside chat today, November 18, at 1:50 PM ET, where we’ll share updates on our progress in developing therapies for immune-mediated diseases. The Climb team will also be participating in one-on-one investor meetings. Can’t attend in person? The presentation will be webcast live, with a replay available afterward on www.ClimbBio.com. Let’s connect—reach out to schedule a meeting! #Stifel2024 #ClimbBio #Innovation #WeClimbTogether

The team at Climb Bio believes that budoprutug has the potential to be a patient-tailored, differentiated, and best-in-class approach with broad utility for the treatment of B-cell-mediated diseases. We are thrilled with the progress we have made in our subcutaneous program that could potentially feature a low volume injection and enable a patient-tailored approach to disease management in the future. #ICYMI Listen to our Investor Day replay (starting at 09:47) to learn more: https://lnkd.in/g4nVmyg5. #ClimbBio #ClimbTogether

Climb Bio is pleased to welcome Douglas E. Williams, Ph.D. as the new Chair of the Board of Directors. With a strong background in immunology research and development, Dr. Williams will bring valuable expertise to our team. Learn more about this exciting appointment: https://loom.ly/UsGS1xg #newhire #immunology #ClimbBio #WeClimbTogether

#ICYMI Climb Bio’s third-quarter earnings report is now available. Recent highlights include: ? We continued our focus on building a leading immune-mediated disease company with the appointments of Douglas E. Williams, Ph.D. as our Chair of the Board of Directors, and Gary Hao, Ph.D. as VP of CMC. ? We received U.S. FDA Clearance of our Investigational New Drug Application (IND) for budoprutug in systemic lupus erythematosus (SLE). ? The Climb Bio team presented additional data from the Phase 1b study of budoprutug in primary membranous nephropathy (pMN) at the American Society of Nephrology Kidney Week 2024. Our journey is just beginning. Read the Q3 earnings press release: https://loom.ly/myqBYwE #ClimbBio #WeClimbTogether

#ICYMI: Climb Bio’s lead program, budoprutug, is a highly potent anti-CD19 monoclonal antibody that has the potential to treat immune-mediated diseases like ITP and pMN. In our Investor Day presentation, Interim Chief Scientific Officer Stephen Thomas, PhD, discussed the scientific rationale behind this approach and the unique attributes that make budoprutug a potential best-in-class, patient-tailored treatment for immune-mediated diseases. Watch the Investor Day replay to learn more about Climb Bio’s vision and strategy—start at 09:47 for the deep dive: https://lnkd.in/g4nVmyg5 #ClimbBio #ClimbTogether

Climb Bio is pleased to welcome Douglas E. Williams, Ph.D. as the new Chair of the Board of Directors. With a strong background in immunology research and development, Dr. Williams will bring valuable expertise to our team. Learn more about this exciting appointment: https://loom.ly/UsGS1xg #newhire #immunology #ClimbBio #WeClimbTogether

Climb Bio is targeting three key areas where budoprutug, an anti-CD19 antibody, can make a meaningful impact: IgG4-mediated diseases, complex systemic diseases like systemic lupus erythematosus, and single-organ diseases such as immune thrombocytopenia. By focusing on these areas, we aim to transform the treatment landscape for patients with B-cell mediated diseases. #ICYMI Watch the replay of our Investor Day: https://lnkd.in/eVGKJwar. #ClimbBio #ClimbTogether